- Home
- IGI vs NTHI Comparison
IGI vs NTHI Comparison
Compare IGI & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IGI | NTHI |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.9M | 106.0M |
| IPO Year | 2009 | 2023 |
Fundamental Metrics
Financial Performance| Metric | IGI | NTHI |
|---|---|---|
| Price | $15.31 | $2.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 10.4K | ★ 138.2K |
| Earning Date | 01-01-0001 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $39,990.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.08 | $2.50 |
| 52 Week High | $16.88 | $12.00 |
Technical Indicators
Market Signals| Indicator | IGI | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 40.70 | 47.02 |
| Support Level | $15.08 | $2.50 |
| Resistance Level | $16.31 | $3.70 |
| Average True Range (ATR) | 0.19 | 0.22 |
| MACD | -0.00 | 0.06 |
| Stochastic Oscillator | 27.86 | 72.97 |
Price Performance
Historical ComparisonAbout IGI Western Asset Investment Grade Defined Opportunity Trust Inc.
Western Asset Invstm Grd Dfnd Opp Tr Inc operates as a non-diversified closed-end management investment company. Its primary investment objective is to provide current income and then liquidate & distribute substantially all of the Fund's net assets to stockholders. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing at least 80% of its net assets in investment-grade corporate fixed-income securities of varying maturities.
About NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.